An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions

Por Kinder, Michelle, Greenplate, Allison R, Strohl, William R, Jordan, Robert E, Brezski, Randall J
Publicado no MAbs (2015)

Hematopoietic stem cell function requires 12/15-lipoxygenase–dependent fatty acid metabolism

Por Kinder, Michelle, Wei, Cong, Shelat, Suresh G., Kundu, Mondira, Zhao, Liang, Blair, Ian A., Puré, Ellen
Publicado em 2010

Irf8-driven myeloid differentiation is regulated by 12/15-lipoxygenase-mediated redox signaling

Por Kinder, Michelle, Thompson, James E., Wei, Cong, Shelat, Suresh G., Blair, Ian A., Carroll, Martin, Puré, Ellen
Publicado em 2010

12/15-Lipoxygenase-Dependent Myeloid Production of Interleukin-12 Is Essential for Resistance to Chronic Toxoplasmosis

Por Middleton, Melissa K., Zukas, Alicia M., Rubinstein, Tanya, Kinder, Michelle, Wilson, Emma H., Zhu, Peijuan, Blair, Ian A., Hunter, Christopher A., Puré, Ellen
Publicado em 2009

TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1

Por Sabins, Nina Chi, Chornoguz, Olesya, Leander, Karen, Kaplan, Fred, Carter, Richard, Kinder, Michelle, Bachman, Kurtis, Verona, Raluca, Shen, Shixue, Bhargava, Vipul, Santulli-Marotto, Sandra
Publicado no J Immunol (2017)

The Tumor Necrosis Factor-Family Receptor DR3 is Essential for Diverse T-Cell Mediated Inflammatory Diseases

Por Meylan, Françoise, Davidson, Todd S., Kahle, Erin, Kinder, Michelle, Acharya, Krishika, Jankovic, Dragana, Bundoc, Virgilio, Hodges, Marcus, Shevach, Ethan M., Keane-Myers, Andrea, Wang, Eddie C.Y., Siegel, Richard M.
Publicado em 2008

A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo

Por Brezski, Randall J, Kinder, Michelle, Grugan, Katharine D, Soring, Keri L, Carton, Jill, Greenplate, Allison R, Petley, Theodore, Capaldi, Dorie, Brosnan, Kerry, Emmell, Eva, Watson, Sharon, Jordan, Robert E
Publicado no MAbs (2014)

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

Por Diamond, Mark S., Kinder, Michelle, Matsushita, Hirokazu, Mashayekhi, Mona, Dunn, Gavin P., Archambault, Jessica M., Lee, Hsiaoju, Arthur, Cora D., White, J. Michael, Kalinke, Ulrich, Murphy, Kenneth M., Schreiber, Robert D.
Publicado em 2011

Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions

Por Kinder, Michelle, Greenplate, Allison R., Grugan, Katharine D., Soring, Keri L., Heeringa, Katharine A., McCarthy, Stephen G., Bannish, Gregory, Perpetua, Meredith, Lynch, Frank, Jordan, Robert E., Strohl, William R., Brezski, Randall J.
Publicado em 2013